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Summary
Background Short-term mortality rates among patients with HIV receiving antiretroviral therapy (ART) in sub-
Saharan Africa are higher than those recorded in high-income countries, but systematic long-term comparisons have 
not been made because of the scarcity of available data. We analysed the eﬀ ect of the implementation of Botswana’s 
national ART programme, known as Masa, from 2002 to 2010.
Methods The Masa programme started on Jan 21, 2002. Patients who were eligible for ART according to national 
guidelines had their data collected prospectively through a clinical information system developed by the Botswana 
Ministry of Health. A dataset of all available electronic records for adults (≥18 years) who had enrolled by April 30, 
2010, was extracted and sent to the study team. All data were anonymised before analysis. The primary outcome was 
mortality. To assess the eﬀ ect of loss to follow-up, we did a series of sensitivity analyses assuming varying proportions 
of the population lost to follow-up to be dead.
Findings We analysed the records of 126 263 patients, of whom 102 713 had documented initiation of ART. Median 
follow-up time was 35 months (IQR 14–56), with a median of eight follow-up visits (4–14). 15 270 patients were 
deemed lost to follow-up by the end of the study. 63% (78 866) of the study population were women; median age at 
baseline was 34 years for women (IQR 29–41) and 38 years for men (33–45). 10 230 (8%) deaths were documented 
during the 9 years of the study. Mortality was highest during the ﬁ rst 3 months after treatment initiation at 12·8 deaths 
per 100 person-years (95% CI 12·4–13·2), but decreased to 1·16 deaths per 100 person-years (1·12–1·2) in the second 
year of treatment, and to 0·15 deaths per 100 person-years (0·09–0·25) over the next 7 years of follow-up. In each 
calendar year after the start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 
101 cells/μL [IQR 44–156] in 2002, to 191 cells/μL [115–239] in 2010). In each year, the proportion of the total enrolled 
population who died in that year decreased, from 63% (88 of 140) in 2002, to 0·8% (13 of 1599) in 2010. A sensitivity 
analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths, increasing 
overall mortality from 8% to 11–13%.
Interpretation The Botswana national HIV/AIDS treatment programme reduced mortality among adults with HIV to 
levels much the same as in other low-income or middle-income countries.
Funding The African Comprehensive HIV/AIDS Partnerships.
Introduction
Starting in 2002, Botswana was the ﬁ rst African country 
to establish a national HIV/AIDS treatment programme, 
calling it “Masa”, the Setswana word for “a new dawn”. 
Before the introduction of Masa, Botswana had one of 
the highest rates of HIV/AIDS in the world. By 2001, the 
national prevalence of HIV/AIDS had reached 27%.1
Key characteristics of Botswana’s antiretroviral therapy 
(ART) programme are that it is free and universal—it is 
open to all citizens who meet the national guidelines; 
however, some of the population have not been tested for 
HIV, and thus their status is not known. In 2008, the 
eligibility criteria for ART changed from a CD4 cell count 
of 200 cells/μL to 250 cells/μL and, in 2013, to 
350 cells/μL.2 Since the start of the Masa programme in 
2002, the national guidelines have changed to take into 
account the improved understanding of the biology of 
HIV, reduce adverse events associated with stavudine and 
zidovudine, and accommodate the availability of improved 
drugs (table). After the 2008 guideline change, tenofovir 
(plus emtricitabine in almost all cases) replaced zidovudine 
as the ﬁ rst-line nucleoside reverse transcriptase inhibitor 
in Botswana. In 2002, 3500 patients were receiving 
treatment. By November, 2012, that number had reached 
201 822 patients treated via more than 200 clinics and 
35 hospitals around the country.
To track patients eligible for ART and monitor the 
progress and eﬀ ectiveness of the Masa programme, the 
Government of Botswana, with the support of the US 
President’s Emergency Plan for AIDS Relief (PEPFAR), 
established a monitoring and evaluation unit within the 
national ART programme in the Department of HIV/
AIDS Prevention and Care of the Ministry of Health. 
This electronic patient tracking and outcomes monitoring 
system has been crucial for the eﬀ ective scale-up of the 
programme. Through capture of individual-level patient 
data, the system is able to generate facility-level reports 
that aid in both clinic management and care of patients. 
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The system allows for collection and analysis of aggregate 
outcome data, encourages compliance with treatment 
protocols, tracks pharmaceutical usage, and generates 
lists of patients needing home follow-up.
Assessment of national ART programmes is essential 
to establish whether programmes are having the desired 
eﬀ ects and to monitor any unanticipated eﬀ ects or 
consequences. Several studies3–15 have shown the 
successful implementation of ART programmes in low-
income and middle-income countries with overall 
outcomes that are much the same as in high-income 
countries. Most reports of ART outcomes, however, have 
come from select cohorts that might not be indicative of 
national programme conditions.6,8,16–20 Additionally, most 
reports have captured national longitudinal outcome 
data for patients receiving ART for only a few years.
We analysed 9 years of follow-up data for more than 
100 000 adult patients who were treated in the Botswana 
national HIV/AIDS treatment programme and tracked at 
individual level in the electronic system described above. 
We aimed to assess mortality, loss to follow-up, changes 
in CD4 cell count after treatment initiation, and other 
predictors of mortality including clinical and 
demographic factors.
Methods
Data
The Masa programme started on Jan 21, 2002. Patients 
who were eligible for ART had their data collected 
prospectively through the Botswana Ministry of Health’s 
clinical information system. Many patients did not have 
an HIV medical ﬁ le created until they were eligible for 
treatment. All hospitals and most clinics had an 
electronic information system by the end of 2012; at the 
time of our data cutoﬀ  in 2010, about 15% clinics were 
not integrated into the national information system.
A dataset of all available electronic records for adults 
(≥18 years; about 18 000 records for patients <18 years 
were excluded from this analysis) who had enrolled by 
April 30, 2010, was extracted from the Ministry of Health 
data warehouse and sent to the study team for this 
analysis. All data were anonymised before the analysis. 
The few patients who had started ART before the launch 
of the national programme in 2002 were excluded because 
their treatment regimen was not necessarily the same as 
recommended by the national guidelines. At the time the 
dataset was transferred from the Ministry of Health for 
this study, not all the available data collected from clinics 
from September, 2009, to April, 2010, had been integrated 
into the central database. However, because all available 
data from the clinics were collected but not yet entered 
into the database, we do not expect non-integrated patient 
data to come from patients (or clinics) whose outcomes 
are systematically diﬀ erent than those included.
This study was reviewed and approved by Harvard School 
of Public Health’s Institutional Review Board and the 
Human Resource Development Committe in Botswana.
Analysis
The primary outcome measure for this analysis was 
mortality. For this assessment, documented death 
referred to a death that was recorded in the database. 
Deaths in hospitals or in other institutions might not be 
reported to HIV clinic staﬀ  and non-institutional deaths 
might not be reported to the health-care system as is 
legally required. Therefore, loss to follow-up might 
include patients who died without a death report captured 
in the database. To assess the eﬀ ect of loss to follow-up 
on the study outcome, we did a series of sensitivity 
analyses assuming varying proportions of the population 
lost to follow-up to be dead. We used number of patients 
whose death was documented in the numerator and 
patient-years of follow-up time in the denominator to 
directly calculate the mortality rate.
We also recorded change in median CD4 cell count and 
viral load over time, for the patients for whom these data 
were available, and type of antiretroviral drugs used.
Role of the funding source  
The funder of the study contributed to the study design, 
writing of the report, and the decision to submit this 
paper for publication. The funder was not involved in the 
data analysis or interpretation; all the authors had full 
access to the data in this study.
Eligible adults First-line regimen Second-line regimen Summary of changes
2002 WHO stages I–II: CD4 cell count 
<200 cells/μL
WHO stages III–IV: all patients
Zidovudine and lamivudine plus efavirenz. 
Zidovudine and lamivudine plus nevirapine 
for women of reproductive potential
Didanosine plus stavudine 
plus nelﬁ navir
··
2005 WHO stages I–II: CD4 cell count 
<200 cells/μL
WHO stages III–IV: all patients
Zidovudine or stavudine plus lamivudine 
and efavirenz. Zidovudine, lamivudine, 
and nevirapine for women of 
reproductive potential
Didanosine plus stavudine 
or zidovudine plus lopinavir 
or ritonavir
Eligible adults and CD4 cell count 
threshold stayed the same. First-line 
and second-line regimen changed
2008 WHO stages I–II: CD4 cell count 
<250 cells/μL
WHO stages III–IV: all patients
Tenofovir and emtricitabine or lamivudine 
with efavirenz. Tenofovir and emtricitabine 
or lamivudine with nevirapine for women 
of reproductive potential
Zidovudine plus lamivudine 
plus lopinavir or ritonavir
CD4 cell count threshold changed 
and ﬁ rst-line and second-line 
regimen changed
*Adults visit clinics every 3 months for the ﬁ rst 2 years, and if stable, every 6 months thereafter.
Table: Summary of Botswana national HIV/AIDS treatment guidelines* 
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Results
The dataset provided by the Ministry of Health contained 
the records for 142 898 adults. The ﬁ rst recorded 
enrolment was on Jan 21, 2002, and the last enrolment in 
the dataset was April 30, 2010; the last recorded visit was 
Dec 31, 2010. We excluded records of 16 635 patients for 
the following reasons: 1144 patients with at least one 
observation after the recorded death; 924 patients with no 
information on drugs, death, or CD4 cell count; 
295 patients with a visit dated outside the timeframe of 
this study; and 14 272 patients with only one observation 
(no follow-up records). The medical records for the 
remaining 126 263 patients were used for the analysis. 
Median follow-up time was 35 months (IQR 14–56), with 
a median of eight follow-up visits (4–14).
In the dataset used for this analysis, the number of 
patients enrolled in the Masa programme increased from 
140 in 2002, to 126 263 by April 30, 2010 (ﬁ gure 1). The 
biggest increase in enrolment, both in absolute number 
and proportion, occurred in 2004, when the national 
rollout programme started, after which the number of 
people in the programme continued to increase albeit at 
diminishing rates, because the population of people with 
HIV who were not already in the programme was 
decreasing. In 2008, the eligibility criteria for ART 
changed from a CD4 cell count of 200 cells/μL to 
250 cells/μL; despite this change, the proportion of 
patients who joined the programme before they were 
eligible for treatment remained relatively stable over 
time (data not shown).
63% of the study population (78 866) were women; 
median age at baseline was 34 years for women 
(IQR 29–41) and 38 years for men (33–45). Of 
126 263 patients included in the analysis, 23 550 did not 
have any ART drugs documented (of whom 8553 were 
eligible and 14 651 were not eligible for ART on the basis 
of their CD4 cell count). 102 713 individuals in the national 
programme had consistent records and documented ART 
provided by either the public or private sector over the 
study period. Of these patients, baseline CD4 cell count 
was available for 68% (69 852). For this analysis, we 
deﬁ ned the last pretreatment CD4 cell count as baseline.
Among patients whose baseline CD4 cell count was 
recorded, the overall median baseline CD4 cell count was 
151 cells/μL (IQR 86–200). The median baseline CD4 cell 
count for men was 134 cells/μL (70–192) and for women 
was 161 cells/μL (97–208). Baseline CD4 cell count was 
between 50 and 150 cells/μL for 36% (25 190) of patients, 
and below 50 cells/μL for 13% (9290). Between Jan 21, 
2002, and May 1, 2008, when the national guidelines set 
the CD4 cell count threshold for treatment initiation at 
200 cells/μL, 25% (17 467 of 69 852) of patients started 
their treatment with CD4 cell counts above this threshold 
because they were diagnosed with stage 3 or 4 disease 
according to the WHO criteria.21 After the eligibility 
criteria increased to 250 cells/μL in 2008, 24 970 patients 
initiated treatment, of whom 12% (2864) had a CD4 cell 
count above 200 cells/μL (the previous threshold) and 
below 250 cells/μL (new threshold). After the guideline 
change in 2008, 16% (3991) of patients started treatment 
because they had stage 3 or 4 disease according to the 
WHO criteria, despite having a CD4 cell count above the 
guideline threshold.
Median baseline CD4 cell count increased in each year 
of analysis, from 101 cells/μL (IQR 44–156) in 2002 to 
191 cells/μL (115–239) in 2010 (ﬁ gure 2). In general, 
patients’ CD4 cell counts increased signiﬁ cantly in the 
ﬁ rst 24 weeks of treatment, followed by a gradual increase 
to 350 cells/μL, on average, after 2 years of treatment. A 
regression model of the quadratic time trend showed 
that patients’ CD4 cell counts increased signiﬁ cantly 
(p<0·0001; ﬁ gure 3). Additional ﬁ tted linear and log-
linear models showed the quadratic time trend to be the 
best ﬁ t to the data.
Baseline viral load was available for 12 606 patients in 
the dataset. The overall median plasma viral load at 
baseline was 4·9 log10 copies/mL (IQR 4·2–5·6). Men 
had slightly higher viral loads than women (median 5·2 
[4·3– 5·7] vs 4·9 [4·1–5·6]).
For the 102 713 patients with data for ﬁ rst-line ART 
drugs available in the database, zidovudine and 
lamivudine were the main nucleoside reverse trans-
criptase inhibitors used, with 78 528 of 101 481 (77%) of 
patients starting on zidovudine (plus lamivudine in 
almost all cases) compared with 7680 of 101 481 (8%) on 
stavudine during the ﬁ rst 5 years of the programme. 
Non-nucleoside reverse-transcriptase inhibitors were 
split between efavirenz (56 829 of 101 311, 56%) and 
nevirapine (44 482 of 101 311, 44%).
10 230 (8%) deaths (50% men, compared with 43% 
men in the dataset) were documented during the 9 years 
Figure 1: Cumulative number of enrolments, mortality, and patients receiving treatment in Botswana’s 
national ART programme, 2002–10
For patients with consistent electronic records in the dataset. ART=antiretroviral therapy.
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of the study (ﬁ gure 1). The mean age of those who died in 
2003 was 35 years (SD 8·3), which increased to 40 years 
(10·0) in 2009. The 9-year mortality rate was 2·71 per 
100 person-years (95% CI 2·66–2·76) with a total follow-
up time of 377 716 person-years. Mortality was greatest 
during the ﬁ rst 3 months of treatment (12·8 deaths per 
100 person-years [12·4–13·2]) but decreased rapidly to 
3·46 deaths per 100 person-years (3·25–3·69) after 
6 months. The mortality rate in the second year of 
treatment was 1·16 deaths per 100 person-years 
(1·12–1·2), and the proportion of patients surviving 
increased over time. Mortality decreased steadily to 
0·15 deaths per 100 person-years (0·09–0·25) over the 
next 7 years of follow-up. In the ﬁ rst year of the 
programme, 29% (51 of 171) of patients died in the ﬁ rst 
year of treatment compared with only 3% (349 of 11 679) 
in 2009. In each year, the proportion of the total enrolled 
population who died in that year decreased, from 63% 
(88 of 140) in 2002, to 0·8% (13 of 1599) in 2010. For 
patients enrolled in 2009, the mortality rate in months 
4–6 of treatment was 2·49 deaths per 100 person-years 
(2·0–3·1), compared with 7·16 deaths per 100 person-
years (6·5–7·9) in months 4–6 of treatment for those 
enrolled in 2004; the mortality rate in months 10–12 of 
treatment for patients enrolled in 2009 was lower than 
the rate in the same months of treatment for those 
enrolled in 2004 (0·67 deaths per 100 person-years 
[0·4–1·1] vs 2·3 deaths per 100 person-years [1·9–2·7] 
(ﬁ gure 4).
15 270 patients were deemed lost to follow-up over the 
whole study period. 5911 patients in the dataset were 
identiﬁ ed by the treatment clinics as lost to follow-up 
because they did not return to a treatment centre for 
more than 90 days. In addition to those identiﬁ ed as lost 
to follow-up by treatment clinics, other issues led us to 
mark patients as lost. Some records were lost because of 
patient transfers between clinics. Of 20 583 transfer cases 
from 2002 to 2010, there were 8384 patients who 
transferred between clinics whose records were not 
linked because of erroneous personal identiﬁ ers. We 
categorised them as lost to follow-up for the purpose of 
this analysis. The medical records for 975 patients 
visiting clinics from September, 2009, to April, 2010, 
were not integrated into the central database because of a 
logistical issue at the Ministry of Health data warehouse 
and were deemed lost to follow-up.
The loss to follow-up during the ﬁ rst year of treatment 
initiation was 21·9% (95% CI 21·6–22·1), with the lowest 
proportion of loss to follow-up being 12·4% (11·98–12·79) 
in 2004, and the highest proportion being 53% 
(53·1–84·66) in 2009. The rate of loss to follow-up in the 
ﬁ rst year after treatment initiation was less than 
ten patients per 100 patient-years up to 2009, when it 
increased to 37 patients per 100 patient-years. However, 
the high proportion and rate of loss to follow-up in 
2009 might be explained by the data that were not 
integrated into the Ministry of Health database after 
September, 2009. Overall, loss to follow-up was 7·3 patients 
per 100 patient-years (7·2–7·4) in the ﬁ rst year after 
treatment initiation, 34·6 patients per 100 patient-years 
(33·9–35·3) in the ﬁ rst 90 days, and 23·7 patients per 
100 patient-years (23·2–24·3) after 90 days.
In the sensitivity analyses, mortality over time 
remained the same with varying proportions of the 
population lost to follow-up assumed to be dead (data not 
shown). Assuming that 60% of the population lost to 
follow-up had died in accordance with available scientiﬁ c 
literature22,23 resulted in 3000 additional deaths, which 
would increase mortality from 8% to 11–13%.
Discussion
Of 126 263 adult patients enrolled in the Botswana 
national ART programme from 2002 to 2010, 102 713 had 
documented initiation of ART. 8% of patients died during 
the 9 years of the study. Mortality was highest during the 
ﬁ rst 3 months after treatment initiation, but decreased 
substantially in the second year of treatment, and 
remained low in subsequent years of follow-up. In each 
calendar year after the start of the programme, average 
CD4 cell counts at enrolment increased. A sensitivity 
Figure 2: Baseline CD4 cell counts
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analysis assuming that 60% of the population lost to 
follow-up had died gave 3000 additional deaths, 
increasing overall mortality from 8% to 11–13%. 
The Government of Botswana has made substantial 
progress in development of health infrastructure 
(including health-care facilities, specialised laboratories, 
information systems, and training of health-care workers) 
to treat large numbers of people with HIV/AIDS across the 
country. The most notable outcome of the rapid scaling up 
of the Botswana national ART programme from 2002 to 
2010, which provided treatment to more than 100 000 
previously ART-naive adult patients with HIV, is its success 
in decreasing mortality from 12·8 deaths per 100 person-
years within 3 months of treatment initiation to 1·16 deaths 
per 100 person-years after a year of ART. This outcome is 
especially impressive in view of the fact that Botswana’s 
population is 2 million with 300 000 (95% CI 
280 000–310 000) individuals estimated to have HIV 
infection.24 This reduction in mortality, to levels much the 
same as in other resource-limited countries,12,14,25,26 was 
sustained across the subsequent 7 years of follow-up. The 
mortality rate after 3 months of treatment in Zambia is 
26 deaths per 100 person-years12 and in China is 22·6 deaths 
per 100 person-years.14 Some researchers have suggested 
that the relatively high mortality within the ﬁ rst few 
months of treatment is attributable to a reconstituting 
immune system.27 Other factors corresponding to 
increased mortality within the ﬁ rst 3 months of ART 
include low baseline CD4 cell count, anaemia, tuberculosis, 
and hepatitis.28,29 The overall mortality in this study was 
2·71 deaths per 100 person-years. This result is similar to 
the 3·7 deaths per 100 person-years calculated in 2 years of 
follow-up in the Rwandan national programme20 and 
substantially lower than the 16·1 deaths per 100 person-
years in Zambia (over 18 months of follow-up).12
Our ﬁ ndings also suggest that mortality after the ﬁ rst 
3 months of treatment is decreasing, since mortality after 
4–6, 7–9, and 10–12 months of treatment was lower for 
patients enrolled in 2009 than for those enrolled in 2004. 
This ﬁ nding can be explained, to some extent, by the fact 
that the system adjusted itself through better trained 
personnel and an improved health information system.
Loss to follow-up, or lack of electronic documentation, 
seems to be an important issue to be addressed, because 
some researchers suggest that retention of patients 
might be a good overall indicator of programme 
eﬀ ectiveness.10 Two systematic reviews7,30 showed that, at 
2 years, African ART programmes retain only about 60% 
of their patients, largely because of high loss to follow-
up. The underlying determinants of this loss are not well 
understood. In their systematic review, Brinkhof and 
colleagues22 showed that, in ART programmes in 
resource-limited settings, a substantial minority of adults 
lost to follow up could not be traced, and among those 
traced 20–60% had died. Using a method to trace 
patients, a study23 of 524 patients in Botswana in early 
2003 showed that more than half of the 68 patients 
originally deemed to be lost to follow-up were conﬁ rmed 
to be dead after tracing. The scientiﬁ c literature regarding 
tracing of patients in ART programmes suggests a 
similarity between those who die among the population 
lost to follow-up and those with documented death in 
terms of summary statistics for risk factors, including 
baseline CD4 cell count, sex, and age.23 In our study, 
patients declared as lost to follow-up by clinics were more 
similar to those with documented death than to those 
who survived, whereas patients deemed lost to follow-up 
because of absence of electronic documentation had 
much the same baseline CD4 cell counts and 
demographic characteristics as the overall study 
population (data not shown). Therefore, we assumed 
60% of patients reported as lost to follow-up by the clinics 
to be dead in our sensitivity analysis, but we did not 
identify any meaningful changes to our results.
The Masa programme is perhaps the largest single 
cohort of patients receiving ART yet to be described. As 
of Nov 30, 2012, more than 201 822 patients had been 
enrolled into HIV care and treatment, and more than 
180 000 had started ART. We believe one of the major 
factors behind the success of the rapid expansion of the 
programme and its favourable clinical outcomes is the 
decision of the Government of Botswana to oﬀ er 
universal free routine testing and counselling and HIV 
care and treatment, despite the negative demographic 
and economic consequences associated with the HIV/
AIDS epidemic. By taking an HIV test publicly in June, 
2003, the President of Botswana started a large public 
awareness campaign against HIV that probably 
contributed to the success of Masa programme.
Another important factor was international donations 
that supported capacity building. The ﬁ nancial resources 
made available by PEPFAR, the African Comprehensive 
HIV/AIDS Partnerships (ACHAP), and other 
international donors have allowed rapid implementation 
and maintenance of the training and information 
systems much needed for this resource-intensive care 
system that has saved many lives.
Figure 4: Mortality in the ﬁ rst year after treatment initiation
Error bars are 95% CI.
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At the outset of the Masa programme, Botswana, like 
other sub-Saharan countries, faced a human resource 
crisis. The country had low physician to patient ratios. 
The challenge was not only the scarcity of all cadres of 
trained health-care workers, because of government 
economic and ﬁ scal constraints, but also the scarcity of 
training mechanisms to meet the demands of the HIV/
AIDS epidemic. At the start of the scale-up process, the 
Ministry of Health of Botswana anticipated that the 
situation would be exacerbated by an increase in the 
volume of patients attending outpatient clinics for HIV-
related care and treatment and consistent over-capacity at 
medical wards. Botswana has circumvented a subset of 
these issues by creating successful partnerships that 
oﬀ er national training programmes for HIV and AIDS 
care. For example, as of 2012, more than 9000 health-care 
workers had received training from the Botswana 
Ministry of Health’s Knowledge Innovation and Training 
Shall Overcome AIDS Training Program, supported by 
ACHAP. Additionally, the PEPFAR Clinical Master 
Training Program oﬀ ers routine, on-site education to 
ensure that health-care professionals stay motivated and 
receive up-to-date training and suﬃ  cient technical 
support on HIV and AIDS care. The country has 
additionally initiated creative partnerships between the 
private and public sectors. The purpose of the 
partnerships was to help alleviate the shortages in the 
public sector by enabling private physicians to share the 
burden of patients. Physicians now receive incentives to 
act as agents of Masa by providing publicly funded 
services. The partnership presents an opportunity for 
expansion of service provision and enables physicians in 
the private sector to have many poor patients who could 
not aﬀ ord their services otherwise.
Our analysis of the Botswana national ART programme 
shows areas of success and areas needing improvement. 
The programme successfully reduced mortality among 
patients with AIDS to levels much the same as those 
reported by other low-income or middle-income 
countries, and continued to improve this low mortality 
rate over the study period. The programme also reduced 
mortality in the ﬁ rst year of treatment initiation; the high 
initial mortality after treatment initiation shows the 
importance of the recent change in the national 
guidelines, which requires earlier treatment, from 
CD4 cell counts below 200 cells/μL in 2002, to below 
250 cells/μL in 2008, and to below 350 cells/μL in 2013. 
The programme encouraged earlier HIV treatment 
through increased screening and worked to reduce 
stigma and discrimination, which deter people from 
being screened and accessing care. As treatment 
improves and patients live longer, the national ART 
programme will need to deal with ART-related toxicities 
and non-AIDS deﬁ ning disorders.31,32
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